Bio-Techne Unveils Groundbreaking Protein Proximity Program
New assay enables high-resolution spatial visualization of protein interactions, unlocking functional insights within complex tissues
Today, Bio-Techne Corporation (NASDAQ: TECH), a prominent name in the life science tools sector, has revealed an exciting Early Access Program. This initiative focuses on a next-generation assay designed for in situ detection of protein proximity. Leveraging Advanced Cell Diagnostics RNAscope™ technology, this assay aims to illuminate the functional interactions among proteins in intact tissues. It represents a significant advancement in spatial biology, helping researchers to explore the intricate dynamics of molecular signaling relevant to disease processes.
Dr. Matt McManus, President of Bio-Techne's Diagnostics & Spatial Biology Segment, emphasized the innovation: "With this new assay, we can now visualize not just the presence of proteins but their functional interactions as well. This is a substantial leap forward in comprehending the dynamic networks present in tissues that underpin critical biological and disease processes."
Traditional methods for examining molecular interactions often measure proteins and RNA separately, potentially compromising spatial accuracy. Additionally, existing bulk proximity assays typically lack the capacity for localization data. Bio-Techne's new proximity detection technology provides a robust solution, offering clear visual signals with subcellular resolution. This capability holds immense promise in various research areas, particularly where understanding spatial context is essential, such as investigating immune checkpoint dynamics and measuring protein interactions in synaptic regions.
The Early Access Program extends an invitation to select academic and research institutions interested in harnessing these spatial protein proximity capabilities. Bio-Techne plans to share proof-of-concept data and case studies during a presentation at the upcoming annual meeting of the American Association for Cancer Research (AACR) in 2025, showcasing the potential applications of this ground-breaking technology.
About Bio-Techne Corporation
Bio-Techne Corporation (NASDAQ: TECH) stands as a leading global life sciences company, offering innovative tools and bioactive reagents aimed at enhancing research and clinical diagnostics. The company’s extensive product portfolio aids scientists in their pursuit of insights into biological processes and the intricacies of disease evolution. Bio-Techne plays a pivotal role in drug discovery while also delivering essential resources for accurate clinical testing and diagnosis. Generating around $1.2 billion in net sales in its latest fiscal year, Bio-Techne boasts a dedicated workforce of approximately 3,100 employees worldwide. For more details about Bio-Techne and its diverse brands, please visit their official website or connect with them on social media platforms.
For investor inquiries, please contact David Clair, Vice President of Investor Relations & Corporate Development, at 612-656-4416.
Frequently Asked Questions
What is the Early Access Program introduced by Bio-Techne?
The Early Access Program allows select researchers to utilize an advanced spatial protein proximity assay for studying interactions in tissues.
What technology does Bio-Techne's new assay utilize?
The new assay is built on Advanced Cell Diagnostics RNAscope™ technology, enhancing protein detection within intact tissues.
How does this assay differ from traditional methods?
Unlike conventional methods that separate measurements for proteins and RNA, this assay provides integrated detection with spatial fidelity.
What are the potential applications of this assay?
The assay can be applied in research areas such as immune checkpoint dynamics, drug discovery, and studying synaptic interactions.
What recent financial achievements has Bio-Techne accomplished?
Bio-Techne reported approximately $1.2 billion in net sales for the fiscal year, indicating its robust growth and market presence.
